Sydnexis

Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia

Company remains committed to ongoing public dialogue on the clinical evidence supporting SYD-101 and the real-world challenges facing children, families, and eye care professionals DEL MAR, Calif., July 13, 2026 [Del Mar, California] — Sydnexis, Inc., a biopharmaceutical company focused…

Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting

DEL MAR, Calif., May 1, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to a prespecified subgroup analysis in children with fast-progressing…

Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting

Comprehensive analyses identified children aged 3 to 12 years and fast progressors with mild to moderate myopia as the populations with greatest treatment benefit  Data demonstrated consistent effects in the largest global pediatric myopia clinical trial to date  SYD-101 well tolerated with no…

Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia

DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the…

Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025

Largest global clinical trial in pediatric myopia met primary efficacy endpoint of proportion of patients with confirmed progression of -0.75D and key secondary endpoint of annual progression rate Treatment effects evident by month 12 and sustained through month 36; greatest treatment benefit…

Sydnexis Wins Poster Session at Vision by Design 2025: Effect of pH and BAK on Pupil Dilation Following Low-dose Atropine Administration in Dutch Belted Rabbits

We’re proud to share that Sydnexis was named the poster session winner at Vision by Design 2025, the annual conference hosted by the American Academy of Orthokeratology and Myopia Control (AAOMC). This event brings together clinicians, researchers, and industry leaders dedicated to advancing the…